此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

使用PD-1抑制剂Cemiplimab进行新辅助治疗梅克尔细胞癌(Tx) (NeoMatryx)

使用PD-1抑制剂Cemiplimab进行新辅助治疗默克尔细胞癌 - 一项随机、双盲、安慰剂对照、非比较性II期研究

The study is a randomized, double blind, placebo-controlled, non-comparative phase II trial that investigates the efficacy of neoadjuvant anti-PD-1 antibody Cemiplimab treatment in patients with clinical stage I or II Merkel cell carcinoma who have have undergone primary tumour excision and are pending sentinel lymph node biopsy.

研究概览

研究类型

介入性

注册 (估计的)

135

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • Baden-Wurttemberg
      • Heidelberg、Baden-Wurttemberg、德国、69120
        • 招聘中
        • Nationales Centrum für Tumorerkrankungen
        • 接触:
          • Jessica Hassel, Prof. Dr.
      • Mannheim、Baden-Wurttemberg、德国、68161
        • 招聘中
        • Universitätsklinikum Mannheim
        • 接触:
          • Jochen Utikal, Prof. Dr.
      • Tübingen、Baden-Wurttemberg、德国、72076
        • 招聘中
        • Universitätsklinikum Tübingen
        • 接触:
          • Ulrike Leiter-Stöppke, Prof. Dr.
    • Bavaria
      • Regensburg、Bavaria、德国、93053
        • 招聘中
        • Universitätsklinikum Regensburg
        • 接触:
          • Sebastian Haferkamp, Prof. Dr.
      • Würzburg、Bavaria、德国、97080
        • 招聘中
        • Universitätsklinikum Würzburg
        • 接触:
          • Anja Gieserich, Dr.
    • Free and Hanseatic City of Hamburg
      • Hamburg、Free and Hanseatic City of Hamburg、德国、20246
        • 招聘中
        • Universitätsklinikum Hamburg-Eppendorf
        • 接触:
          • Christoffer Gebhardt, Prof. Dr.
    • Hesse
      • Frankfurt am Main、Hesse、德国、60590
        • 招聘中
        • Universitätsklinikum Frankfurt
        • 接触:
          • Bastian Schilling, Prof. Dr.
    • North Rhine-Westphalia
      • Bielefeld、North Rhine-Westphalia、德国、33647
        • 招聘中
        • Klinikum Bielefeld
        • 接触:
          • Selma Ugurel, Prof. Dr.
      • Essen、North Rhine-Westphalia、德国、45147
        • 招聘中
        • Universitätsklinikum Essen
        • 接触:
          • Dirk Schadendorf, Prof. Dr.
      • Minden、North Rhine-Westphalia、德国、32429
        • 尚未招聘
        • Johannes Wesling Klinikum Minden
        • 接触:
          • Ralf Gutzmer, Prof. Dr.
    • Rhineland-Palatinate
      • Mainz、Rhineland-Palatinate、德国、55131
        • 招聘中
        • Universitätsmedizin Mainz
        • 接触:
          • Stefan Grabbe, Prof. Dr.
    • Thuringia
      • Erfurt、Thuringia、德国、99089
        • 招聘中
        • Helios Klinikum Erfurt
        • 接触:
          • Rudolph Herbst, Prof. Dr.

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion criteria

  1. Patient has signed informed written consent.

  2. Patients is 18 years and older at time of signing of written informed consent

  3. Patient has diagnosis of Merkel cell carcinoma in clinical stage II, or in stage I with minimum diameter of 1 cm, with primary tumor already removed and a planned sentinel lymph nodes biopsy still pending.

  4. Patient has ECOG performance status 0-2.

  5. Patients has adequate laboratory parameters particularly for the blood count, renal and liver function parameters.

    1. Absolute number of neutrophils ≥ 1.5 x 109/L
    2. Platelets ≥ 75 x 109/L
    3. Hemoglobin ≥ 9 g/dL
    4. Total bilirubin ≤ 1.5 times the upper limit of normal (ULN) (patients with Gilbert´s Disease and total bilirubin up to 3x ULN may be eligible after approval from trial's medical expert)
    5. AST (SGOT) and ALT (SGPT) ≤ 3x ULN
    6. AP ≤ 2.5x ULN
    7. Serum creatinine ≤ 2x ULN or creatinine clearance ≥ 40 mL/min
  6. Female patients of childbearing potential and male patients with female partners of childbearing potential must agree to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of <1% per year during the treatment period and for at least 6 months after the last dose of Cemiplimab. Male patients must refrain from donating sperm during this same period. Male patients with a pregnant partner must agree to remain abstinent or to use a condom for the duration of the pregnancy.

  7. Patient must be willing to allow translational work-up of tissue samples (PT, sentinel lymph node biopsy).

Exclusion criteria

  1. Patient has prior sentinel lymph node removal for the current MCC.

  2. Patients received prior treatment with immunotherapy (such as PD-1/PD-L1 or CTL4) or any other systemic anti-tumor (MCC) therapy (incl. investigational therapies)

  3. Patient has active or a history of hematological neoplasms including chronic lymphocytic leukemia (CLL), irrespective if these require treatment or not.

  4. Patient had prior organ transplantation including allogenic stem-cell transplantation.

  5. Patient receives immunosuppressive concomitant medication, EXCEPT for the following:

    i. Intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection).

    ii. Systemic corticosteroids at physiologic doses ≤ 10 mg/day of prednisone or equivalent.

    iii. Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication).

  6. Patient has known hypersensitivity to any component of the Cemiplimab formulation as well as a known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion protein.

  7. Patient has active autoimmune or inflammatory disorders.

  8. Patient has history of interstitial lung disease.

  9. Patient has active infection requiring systemic therapy.

  10. Patient has Active infection requiring systemic therapy, including uncontrolled HIV, HBV and HCV infection or diagnosis of immunodeficiency.

    NOTE: Patients are eligible if:

    • Patients have controlled HIV infection with CD4 counts is > 350 cells/μL and viral load is undetectable [HIV RNA PCR]. Patients with controlled HIV infection must be monitored per local standards during the trial.
    • Patients positive for HBV surface antigen have controlled HBV infection receiving anti-viral therapy and with undetectable serum viral load [HBV DNA PCR]. Patients with controlled infection must undergo periodic monitoring of HBV DNA and p must remain on anti-viral therapy for at least 6 months after last dose of Cemiplimab.
    • Patients positive for HCV antibody have controlled HCV infection with undetectable viral load [HCV RNA PCR].
  11. Patent received vaccination with any live vaccine (e.g., intranasal flu vaccine) within 4 weeks before the first dose of Cemiplimab or planned vaccination with live vaccine during the trial

  12. Female patients, who are pregnant or breast feeding or planning to become pregnant within and 6 months after the end of treatment. Female patients of childbearing potential must have a negative serum β-HCG pregnancy test result within 7 days prior to initiation of study treatment.

  13. Patient has evidence of any other disease, neurologic or metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of any of the study medications, puts the patient at higher risk for treatment-related complications or may affect the interpretation of study results.

  14. Patient has known substance abuse or other psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results

  15. Patient is legally incapacitated or has limited legal capacity

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:Arm A (Cemiplimab)

2 cycles of Cemiplimab (350 mg, i.v., Q3W) followed by sentinel lymph node biopsy

Patients will receive Cemiplimab 350 mg i.v. on day 1 of every 21 days cycle for 2 cycles

其他名称:
  • 利比塔约
安慰剂比较:Arm B (placebo)

2 cycles of placebo followed by sentinel lymph node biopsy

Patients will receive NaCl 0.9% solution i.v. on day 1 of every 21 days cycle for 2 cycles.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Nodal micrometastases-free rate
大体时间:up to 36 months

rate of patients without nodal micrometastases after 2 cycles of treatment, determined by sentinel lymph node biopsy

up to 36 months

次要结果测量

结果测量
措施说明
大体时间
Recurrence-free survival
大体时间:up to 66 months

time from randomization until date of the first of the following events: MCC recurrence, and MCC-related death

up to 66 months
Time to recurrence
大体时间:up to 66 months

defined as time from randomization until date of first MCC recurrence

up to 66 months
Overall survival
大体时间:up to 66 months

time from randomization until date of death from any cause

up to 66 months
Quality of life using FCRI-SF questionnaire
大体时间:up to 66 months

Quality of life determined using the FCRI-SF questionnaire

up to 66 months
Safety (AEs and SAEs)
大体时间:up to 66 months

incidence, nature, causality, frequency, timing and severity of adverse events using NCI CTCAE 5

up to 66 months
Disease specific survival
大体时间:up to 66 months

time from randomization until date of MCC-related death

up to 66 months
Quality of life using the mFACT-M questionnaire
大体时间:up to 66 months

Quality of life determined using the mFACT-M questionnaire

up to 66 months

其他结果措施

结果测量
措施说明
大体时间
Investigation of prognostic and predictive biomarkers to estimate the risk of lymph node metastases and signs of immune activation in the sentinel lymph nodes
大体时间:up to 66 months

Biosamples will be used to determine the correlation of identified biomarkers with clinical outcome, i.e., nodal metastases-free rate, RFS, OS

up to 66 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Salah Al-Batran, Prof. Dr.、Institut für Klinische Krebsforschung IKF GmbH
  • 首席研究员:Ralf Gutzmer, Prof. Dr. med.、Johannes Wesling Klinikum Minden
  • 首席研究员:Juergen C. Becker, Prof. Dr. Dr.、Translational Skin Cancer Research University Duisburg-Essen, Germany

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年5月29日

初级完成 (估计的)

2029年12月31日

研究完成 (估计的)

2031年7月31日

研究注册日期

首次提交

2026年1月28日

首先提交符合 QC 标准的

2026年1月28日

首次发布 (实际的)

2026年2月4日

研究记录更新

最后更新发布 (实际的)

2026年11月9日

上次提交的符合 QC 标准的更新

2026年11月4日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅